Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

Gemtuzumab ozogamicin (GO, Mylotarg(®)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Int J Mol Sci
Hoofdauteurs: Fenwarth, Laurène, Fournier, Elise, Cheok, Meyling, Boyer, Thomas, Gonzales, Fanny, Castaigne, Sylvie, Boissel, Nicolas, Lambert, Juliette, Dombret, Hervé, Preudhomme, Claude, Duployez, Nicolas
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: MDPI 2020
Onderwerpen:
Review
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7460695/
https://ncbi.nlm.nih.gov/pubmed/32781546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21165626
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items